PB 39 of 2011
National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2011 (No. 5)
 
National Health Act 1953
___________________________________________________________________________
 
I, FELICITY MCNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated    27 May 2011
 
 
 
 
 
 
 
 
 
 
 
FELICITY MCNEILL
Acting First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________
 
 
 
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2011 (No.5).
 
(2)                This Instrument may also be cited as PB 39 of 2011.
 
2                Commencement
                            This Instrument commences on 1 June 2011.
3              Amendments to PB 117 of 2010
                       Schedule 1 amends the National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement 2010 (PB 117 of 2010).
.
 
Schedule 1                   Amendments
 
       
[1]   Schedule 1, entry for Bleomycin:
             substitute:
 

Bleomycin
Powder for injection containing bleomycin sulphate 15,000 I.U. (with any determined brand of sodium chloride injection as the required solvent)
Injection
Blenamax
QA
EMP
C1139
C1198
 
10
0
 

 
 
 
Hospira Pty Limited
HH
EMP
C1139
C1198
 
10
0
 

 
[2]   Schedule 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL for the brand Docetaxel Ebewe with a maximum quantity of 1 and a number of repeats of 0:
            omit from the column headed “Circumstances”:
 
           C2439
           C3292
 
[3]   Schedule 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL for the brand Docetaxel Ebewe with a maximum quantity of 2 and a number of repeats of 0:
 
              (a) omit from the column headed “Circumstances”:
 
           C2439
           C3292
 
          (b) omit from the column headed “Purposes”:
 
           P2439
           P3292
 
[4]   Schedule 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 8 mL for the brand Docetaxel Ebewe:
            omit from the column headed “Circumstances”:
 
            C2439
            C3292
 
[5]   Schedule 1, entry for Thiotepa:
      substitute:
 
Thiotepa
Powder for injection 15 mg
Injection/
intravesical 
 
Aspen Pharma Pty Ltd
QA
EMP
 
 
 
2
1
 
 
[6]   Schedule 2,
             after:
PL
The Trustee for Virgo Unit Trust (trading as Phebra)
77 695 661 635
             insert:
QA
Aspen Pharma Pty Ltd
88 004 118 594
 
[7]   Schedule 2,
          after:
SH
Schering-Plough Pty Limited
57 000 235 245
         omit:
SI
Sigma Pharmaceuticals (Australia) Pty Ltd
88 004 118 594
 
 
 
 
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 
See http://www.frli.gov.au.